Central and Local Pathology Assessment.Gluz, Oleg; Nitz, Ulrike A; Christgen, Matthias; Kates, Ronald E; Shak, Steven; Clemens, Michael; Kraemer, Stefan; Aktas, Bahriye; Kuemmel, Sherko; Reimer, Toralf; Kusche, Manfred; Heyl, Volker; Lorenz-Salehi, Fatemeh; Just, Marianne;Hofmann, Daniel; Degenhardt, Tom; Liedtke, Cornelia; Svedman, Christer; Wuerstlein, Rachel; Kreipe, Hans H; Harbeck, Nadia.J Clin Oncol; 34(20): 2341-9, 2016 Jul 10.54.Prognostic factor analysis for breast cancer using gene expression profiles.Joe, Soobok; Nam, Hojung.BMC Med Inform Decis Mak; 16 Suppl 1: 56, 2016.55.The Prognostic Impact of Molecular Subtypes and Very Young Age on Breast Conserving Surgery in Early Stage Breast Cancer.Ordu, Cetin; McGuire, Kandace; Alco, Gul; Nur Pilanci, Kezban; Koksal, Ulkuhan I; Elbuken, Filiz; Erdogan, Zeynep;Agacayak, Filiz; Ilgun, Serkan; Sarsenov, Dauren; Ozturk, Alper; Igdem, Sefik; Okkan, Sait; Eralp, Yesim; Dincer, Maktav;Ozmen, Vahit.Cureus; 8(6): e633, 2016.56.Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.Jueckstock, Julia; Rack, Brigitte; Friedl, Thomas W P; Scholz, Christoph; Steidl, Julia; Trapp, Elisabeth; Tesch, Hans;Forstbauer, Helmut; Lorenz, Ralf; Rezai, Mahdi; Haberle, Lothar; Alunni-Fabbroni, Marianna; Schneeweiss, Andreas;Beckmann, Matthias W; Lichtenegger, Werner; Fasching, Peter A; Pantel, Klaus; Janni, Wolfgang.BMC Cancer; 16: 401, 2016.57.Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.Netanely, Dvir; Avraham, Ayelet; Ben-Baruch, Adit; Evron, Ella; Shamir, Ron.Breast Cancer Res; 18(1): 74, 2016.58.Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.Jansson, Sara; Bendahl, Par-Ola; Larsson, Anna-Maria; Aaltonen, Kristina E; Ryden, Lisa.BMC Cancer; 16: 433, 2016.59.Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis.Nottegar, A; Veronese, N; Senthil, M; Roumen, R M; Stubbs, B; Choi, A H; Verheuvel, N C; Solmi, M; Pea, A; Capelli, P;Fassan, M; Sergi, G; Manzato, E; Maruzzo, M; Bagante, F; Koc, M; Eryilmaz, M A; Bria, E; Carbognin, L; Bonetti, F;Barbareschi, M; Luchini, C.Eur J Surg Oncol; 42(7): 919-25, 2016 Jul.60.Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.Dai, Xiaofeng; Xiang, Liangjian; Li, Ting; Bai, Zhonghu.J Cancer; 7(10): 1281-94, 2016.61.PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker.Guo, Lei; Li, Wenbin; Zhu, Xinxin; Ling, Yun; Qiu, Tian; Dong, Lin; Fang, Yi; Yang, Hongying; Ying, Jianming.Springerplus; 5(1): 805, 2016.62.Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.Hida, Akira I; Sagara, Yasuaki; Yotsumoto, Daisuke; Kanemitsu, Shuichi; Kawano, Junko; Baba, Shinichi; Rai, Yoshiaki;Oshiro, Yumi; Aogi, Kenjiro; Sagara, Yoshiaki; Ohi, Yasuyo.Breast Cancer Res Treat; 158(1): 1-9, 2016 Jul.63.HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.Kurozumi, Sasagu; Padilla, Mary; Kurosumi, Masafumi; Matsumoto, Hiroshi; Inoue, Kenichi; Horiguchi, Jun; Takeyoshi, Izumi; Oyama, Tetsunari; Ranger-Moore, Jim; Allred, D Craig; Dennis, Eslie; Nitta, Hiroaki.Breast Cancer Res Treat; 158(1): 99-111, 2016 Jul.64.Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer.Jurikova, Miroslava; Danihel, Ludovit; Polak, Stefan; Varga, Ivan.Acta Histochem; 118(5): 544-52, 2016 Jun.65.Predictive Value of Molecular Subtyping for Locoregional